AI-PROGNOSIS - AI-based Parkinson's disease risk assessment and prognosis.
About Parkinson's disease
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, affecting ~10 million people worldwide, and this number is projected to almost double by the year 2040.
PD is often missed or misdiagnosed, as early symptoms are subtle and common with other diseases. Effective, symptomatic treatments are available, yet selecting the optimal regimen is usually a lengthy, “trial and error” process, leading to unnecessary suffering. Overall costs to Europe have been estimated at ~€13.9 billion annually, with the cost per patient increasing with severity.
With the AI-PROGNOSIS project, we aim to advance Parkinson’s disease diagnosis and care through novel predictive models combined with digital biomarkers from everyday devices.
Following a trustworthy and inclusive approach to AI development and through multidisciplinary expertise and broad stakeholder engagement, we will attempt to fulfill our vision by:
Developing novel, predictive AI models for personalised PD risk assessment and prognosis (regarding disease progression and patients' response to medication) based on multi-source patient records and databases, including in-depth health, phenotypic and genetic data.
Implementing a system of digital biomarkers informing the AI models by tracking key risk and progression markers, such as REM behaviour disorder and key motor symptoms, in daily living based on smartphone and wearable data.
Translating the models and digital biomarkers into a validated, privacy-aware AI-driven toolkit, supporting healthcare professionals in disease screening, monitoring and treatment optimisation, via quantitative, explainable evidence, and offering individuals with/without PD tailored insights.